Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder

NCT02684279 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT02684279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02684279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2016
Completion date
June 24, 2019
Enrollment
533 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

binge eating disorder